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INSOLUBLE DRUG DELIVERY 
RELATED APPLICATIONS 
This application is a continuation of U.S. application Ser. 
No. 09/202,504 filed Oct. 17, 1996, issued as U.S. Pat. No. 
6,576,264, which is a 371 of PCT/US96/16841 filed Oct. 17, 
1996, which claims the benefit of U.S. Application Ser. No. 
60/005,340 filed Oct. 17, 1995. 
This invention provides a novel proceSS for producing 
Sub-micron sized particles of water insoluble compounds 
with biological uses, particularly water insoluble drugs. 
BACKGROUND AND SUMMARY OF THE 
INVENTION 
Approximately one-third of the drugs in the United States 
Pharmacopoeia are water-insoluble or poorly water-Soluble. 
Many currently available injectable formulations of Such 
drugs carry important adverse warnings on their labels that 
originate from detergents and other agents used for their 
solubilization. Oral formulations of water-insoluble drugs or 
compounds with biological uses frequently show poor and 
erratic bioavailability. In addition, water-solubility problems 
delay or completely block the development of many new 
drugs and other biologically useful compounds. 
Two alternative approaches for insoluble drug delivery 
are microparticles which involves forming a phospholipid 
Stabilized acqueous Suspension of Submicron sized particles 
of the drug (see U.S. Pat. Nos. 5,091,187; 5,091,188 and 
5,246,707) and microdroplets which involves forming a 
phospholipid stabilized oil in water emulsion by dissolving 
the drug in a Suitable bio-compatible hydrophobic carrier 
(see U.S. Pat. Nos. 4,622,219 and 4,725,442). 
The pharmacokinetic properties of both oral and inject 
able microparticle formulations are dependent on both the 
particle size and phospholid Surface modifier. However, with 
certain water insoluble compounds the current employed 
methods of particle size reduction are problematic. Thus, the 
overall objective of this invention is to develop a novel 
proceSS based on the use of compressed fluids, including 
Supercritical fluid technology, that yields Surface modifier 
Stabilized Suspensions of water insoluble drugs with an 
average particle size of 100 nm to about 300 nm and a 
narrow Size distribution. The inventive proceSS is robust, 
Scalable and applicable to a wide range of water-insoluble 
compounds with biological uses. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The invention is further explained with reference to the 
attached drawings in which 
FIG. 1 is a Schematic representation of an apparatus for 
carrying out the present invention by precipitating the bio 
active Substance by rapid expansion from a Supercritical 
Solution; 
FIG. 2A is a more detailed representation of the preheater 
assembly of FIG. 1; 
FIG. 2B is an enlarged perspective View of the expansion 
nozzle of FIG. 1; 
FIG. 3 is a Schematic representation of an apparatus for 
preparing Sub-micronsized particles according to the inven 
tion by precipitating a bioactive Substance, Suitably 
Solubilized, into a compressed gas, liquid or Supercritical 
fluid; 
FIG. 4 is a graph showing the particle Size distribution on 











duced in Example 1 expanded into a phospholipid contain 
ing 1 wt % stabilizer; 
FIG. 5 is a graph showing the particle size distribution on 
a volume weighted basis of the cycloSporine particles pro 
duced in Example 1 expanded into a phospholipid contain 
ing 2 wt % stabilizer; 
FIG. 6 is a graph showing the particle Size distribution on 
a volume weighted basis of the indomethacin particles 
produced in Example 3 Sprayed directly into carbon dioxide; 
FIG. 7 is a graph showing the particle size Gaussian 
distribution on a Volume weighted basis of the indomethacin 
particles produced in Example 3 Sprayed into a phospholipid 
containing 2 wt % Stabilizer; 
FIG. 8 is a graph showing the particle size distribution on 
a Volume weighted basis of the tetracaine hydrochloride 
particles produced in Example 4 sprayed into carbon dioxide 
and water; 
FIG. 9 is a graph showing the particle size distribution on 
a Volume weighted basis of the tetracaine hydrochloride 
particles produced in Example 4 sprayed into carbon dioxide 
and water also containing 1 wt % of Stabilizer; and 
FIG. 10 is a graph showing the particle size Gaussian 
distribution on a Volume weighted basis of tetracaine hydro 
chloride particles produced in Example 4 sprayed into 
carbon dioxide, water and 2 wt % stabilizer. 
DESCRIPTION OF THE INVENTION 
This invention is a proceSS using compressed fluids to 
produce Submicron sized particles of industrially useful 
poorly Soluble or insoluble compounds with biological uses 
by: (1) precipitating a compound by rapid expansion from a 
Supercritical Solution (Rapid expansion from Supercritical 
Solution) in which the compound is dissolved, or (2) pre 
cipitating a compound by Spraying a Solution, in which the 
compound is Soluble, into compressed gas, liquid or Super 
critical fluid which is miscible with the Solution but is 
antisolvent for the compound. In this manner precipitation 
with a compressed fluid antisolvent (Compressed fluid 
antisolvent) is achieved. Optionally, the process combines or 
integrates a phospholipid in water or other Suitable Surface 
modifierS Such as Surfactants, as may be required, into the 
processes. The Surfactant is chosen to be active at the 
compound-water interface, but is not chosen to be active at 
the carbon dioxide-organic Solvent or carbon dioxide com 
pound interface when carbon dioxide is used as the Super 
critical Solution. A unique feature of this invention is the 
combination of either rapid expansion from Supercritical 
solution or compressed fluid antisolvent with recovery of 
Surface modified Stable Submicron particles in an aqueous 
phase. 
By industrially useful insoluble or poorly soluble com 
pounds we include biologically useful compounds, imaging 
agents, pharmaceutically useful compounds and in particular 
drugs for human and veterinary medicine. Water insoluble 
compounds are those having a poor Solubility in water, that 
is less than 5 mg/ml at a physiological pH of 6.5 to 7.4, 
although the water Solubility may be less than 1 mg/ml and 
even less than 0.1 mg/ml. 
Examples of Some preferred water-insoluble drugs 
include immunosuppressive and immunoactive agents, anti 
Viral and antifungal agents, antineoplastic agents, analgesic 
and anti-inflammatory agents, antibiotics, anti-epileptics, 
anesthetics, hypnotics, Sedatives, antipsychotic agents, neu 
roleptic agents, antidepressants, anxiolytics, anticonvulsant 
agents, antagonists, neuron blocking agents, anticholinergic 
US 6,974,593 B2 
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and cholinomimetic agents, antimuscarinic and muscarinic 
agents, antiadrenergic and antiarrhythmics, antihypertensive 
agents, antineoplastic agents, hormones, and nutrients. A 
detailed description of these and other Suitable drugs may be 
found in Remington's Pharmaceutical Sciences, 18th 
edition, 1990, Mack Publishing Co. Philadelphia, Pa. 
CycloSporine, a water insoluble immunosuppressive drug, 
is used as a model to illustrate the invention. This drug was 
chosen Since it has not been possible by using conventional 
Size reduction techniques to achieve the particle size and 
distribution believed necessary to reach the desired pharma 
cokinetic performance. 
CycloSporine is a water insoluble, lipophilic 11 amino 
acid polypeptide with unique immunosuppressive proper 
ties. Its major use is as an immunosuppreSSant in Solid organ 
transplantation. The clinical utility of the currently available 
pharmaceutical dosage forms are Severely limited by the 
drugs insolubility. That is, the bioavailability of the oral 
form is low and the intra and inter patient absorption is 
variable. 
The phospholipid may be any natural or Synthetic 
phospholipid, for example phosphatidylcholine, 
phosphatidyle thanolamine, phosphatidyl Serine, 
phosphatidylinositol, phosphatidylglycerol, phosphatidic 
acid, lySophospholipids, egg or Soybean phospholipid or a 
combination thereof The phospholipid may be salted or 
deSalted, hydrogenated or partially hydrogenated or natural 
Semisynthetic or Synthetic. 
Examples of Some Suitable Second Surface modifiers 
include: (a) natural Surfactants Such as casein, gelatin, 
tragacanth, Waxes, enteric resins, paraffin, acacia, gelatin, 
cholesterol esters and triglycerides, (b) nonionic Surfactants 
Such as polyoxyethylene fatty alcohol ethers, Sorbitan fatty 
acid esters, polyoxyethylene fatty acid esters, Sorbitan 
esters, glycerol monoStearate, polyethylene glycols, cetyl 
alcohol, cetostearyl alcohol, Stearyl alcohol, poloxamers, 
polaxamines, methylcellulose, hydroxycellulose, hydroxy 
propylcellulose, hydroxy propylmethylcellulose, noncryS 
talline cellulose, polyvinyl alcohol, polyvinylpyrrolidone, 
and Synthetic phospholipids, (c) anionic Surfactants Such as 
potassium laurate, triethanolamine Stearate, Sodium lauryl 
Sulfate, alkyl polyoxyethylene Sulfates, Sodium alginate, 
dioctyl Sodium SulfoSuccinate, negatively charged phospho 
lipids (phosphatidyl glycerol, phosphatidyl inoSite, 
phosphatidylserine, phosphatidic acid and their salts), and 
negatively charged glyceryl esters, Sodium 
carb oxy methylcellulose, and calcium 
carboxymethylcellulose, (d) cationic Surfactants Such as 
quaternary ammonium compounds, benzalkonium chloride, 
cetyltrimethylammonium bromide, chitosans and lauryldim 
ethylbenzylammonium chloride, (e) colloidal clays Such as 
bentonite and Veegum. A detailed description of these Sur 
factants may be found in Remington's Pharmaceutical 
Sciences, and Theory and Practice of Industrial Pharmacy, 
Lachman et al., 1986. 
More specifically, examples of Suitable Second Surface 
modifiers include one or combination of the following: 
polaxomers, such as PluronicTM F68, F108 and F127, which 
are block copolymers of ethylene oxide and propylene oxide 
available from BASF, and poloxamines, such as TetronicTM 
908 (T908), which is a tetrafunctional block copolymer 
derived from Sequential addition of ethylene oxide and 
propylene oxide to ethylene-diamine available from BASF, 
TritonTM X-200, which is an alkyl aryl polyether sulfonate, 
available from Rohm and Haas. Tween 20, 40, 60 and 80, 











able from ICI Speciality Chemicals, CarbowaxTM 3550 and 
934, which are polyethylene glycols available from Union 
Carbide, hydroxy propylmethylcellulose, dimyristoyl phos 
phatidylglycerol Sodium Salt, Sodium dodecylsulfate, 
Sodium deoxycholate, and cetyltrimethylammonium bro 
mide. 
Particles produced by the process of this invention are 
generally at most 500 nm in size usually below 300 nm, 
desirably less than 200 nm, preferably less than about 100 
nm and often in a range of 0.1 to 100 nm in size. These 
particles are narrowly distributed in that 99% of the particles 
are below 500 nm and preferably below 400 nm with peaks 
at half width at half height at about 200 nm and preferably 
below 100 nm. The particles may be recovered from sus 
pension by any convenient means Such as Spray drying, 
lyophilization, diafiltration, dialysis or evaporation. 
The Solvent properties of Supercritical fluids are Strongly 
affected by their fluid density in the vicinity of the fluids 
critical point. In rapid expansion from Supercritical 
Solutions, a non Volatile Solute is dissolved in a Supercritical 
fluid. Nucleation and crystallization are triggered by reduc 
ing the Solution density through rapid expansion of the 
Supercritical fluid to atmospheric conditions. To achieve this 
the Supercritical fluid is typically sprayed through 10-50 
microns (internal diameter) nozzles with aspect ratios (L/D) 
of 5-100. The fluid approaches Sonic terminal velocity at the 
nozzle tip and high levels of SuperSaturation result in rapid 
nucleation rates and limited crystal growth. The combina 
tion of a rapidly propagating mechanical perturbation and 
high SuperSaturation is a distinguishing feature of rapid 
expansion from a Supercritical Solution. These conditions 
lead to the formation of very small particles with a narrow 
particle distribution. 
The first comprehensive Study of rapid expansion from a 
Supercritical solution was reported by Krukonis (1984)V.J. 
Krukonis: AIChE Annual Meeting San Francisco (1984), as 
cited in J. W. Tom et al.: Supercritical Fluid Engineering 
Science, Chapter 19, p238, (1993) who formed micro 
particles of an array of organic, inorganic, and biological 
materials. Most particle sizes reported for organic materials, 
Such as lovastatin, polyhydroxyacids, and meVinolin, were 
in the 5-100 micron range. Nanoparticles of beta-caroteine 
(300 nm) were formed by expansion of ethane into a viscous 
gelatin Solution in order to inhibit post expansion particle 
aggregation. 
Most rapid expansion from Supercritical Solution Studies 
on organic materials utilize Supercritical carbon dioxide. 
However, ethane was preferred to carbon dioxide for beta 
caroteine because of certain chemical interactions. Carbon 
dioxide is generally preferred, alone or in combination with 
a coSolvent. Minute additions of a coSolvent can increase the 
solubility of some solutes by orders of magnitude. When 
coSolvents are used in rapid expansion from a Supercritical 
Solution, care is required to prevent desolution of the par 
ticles due to Solvent condensing in the nozzle. Normally, this 
is achieved by heating, the Supercritical fluid, prior to 
expansion, to a point where no condensate (mist) is visible 
at the nozzle tip. 
A similar problem occurs when carbon dioxide is used 
alone. During adiabatic expansion (cooling), carbon dioxide 
will be in two phases unless sufficient heat is provided at the 
nozzle to maintain a gaseous State. Most investigators rec 
ognize this phenomenon and increase the pre-expansion 
temperature to prevent condensation and freezing in the 
nozzle. A significant heat input is required (40–50 kcal/kg) 
to maintain carbon dioxide in the gaseous State. If this 
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energy is Supplied by increasing the pre-expansion tempera 
ture the density drops and consequently reduces the Super 
critical fluid's Solvating power. This can lead to premature 
precipitation and clogging of the nozzle. 
There are a number of advantages in utilizing compressed 
carbon dioxide in the liquid and Supercritical fluid States, as 
a solvent or anti-solvent for the formation of materials with 
Submicron particle features. Diffusion coefficients of organic 
Solvents in Supercritical fluid carbon dioxide are typically 
1-2 orders of magnitude higher than in conventional liquid 
Solvents. Furthermore, carbon dioxide is a Small linear 
molecule that diffuses more rapidly in liquids than do other 
antisolvents. In the antisolvent precipitation process, the 
accelerated mass transfer in both directions can facilitate 
very rapid phase Separation and hence the production of 
materials with Sub-micron features. It is easy to recycle the 
Supercritical fluid Solvent at the end of the process by Simply 
reducing pressure. Since Supercritical fluids do not have a 
Surface tension, they can be removed without collapse of 
Structure due to capillary forces. Drying of the product is 
unusually rapid. No carbon dioxide residue is left in the 
product, and carbon dioxide has a number of other desirable 
characteristics, for example it is non-toxic, nonflammable, 
and inexpensive. Furthermore, Solvent waste is greatly 
reduced Since a typical ratio of antisolvent to Solvent is 30:1. 
AS an antisolvent, carbon dioxide has broad applicability 
in that it lowers the cohesive energy of nearly all organic 
solvents. In 1992, D.J. Dixon, PhD. Dissertation, University 
of Texas at Austin, described a process in which liquid 
Solutions of polymer in Solvent are sprayed into compressed 
carbon dioxide to form microspheres and fibers. In this 
process, so called precipitation with a compressed fluid 
antisolvent, the polymer is insoluble in carbon dioxide, and 
the organic solvent is fully miscible with CO. This concept 
has been used to form biologically active insulin particles (4 
microns) Yeo, S. D., Lim, G. B. and Debenedetti, P. G. 
Formation of Microparticulate Protein Powders using a 
Supercritical Fluid Anti-Solvent Biotechnol, and Bioeng. 
1993, 341), several micron biodegradable L-poly(lactic 
acid) particles Randolph, T. W. B., R. A.; Johnston, K. P. 
Micron Sized Biodegradeable Particles of Poly(L-lactic 
Acid) via the Gas Antisolvent Spray Precipitation Process. 
Biotechnology Progress. 1993, 9,429 and methylpredniso 
lone acetate particles (<5 microns) W. J. Schmitt, M. C. S., 
G. G. Shook, S. M. Speaker. Finely-Divided Powders by 
Carrier Solution Injection into a Near or Supercritical Fluid. 
Am. Inst. Chem. Eng. J. 1995, 41, 2476-2486). Somewhat 
Surprisingly, the particle sizes have been as Small as those 
made by rapid expansion from a Supercritical Solution, 
despite the potentially faster times for depressurization in 
rapid expansion from a Supercritical Solution versus two 
way mass transfer in the Compressed fluid antisolvent 
process. Not only can the compressed fluid antisolvent 
process produce PS particles, but also solid and hollow 
fibers highly oriented microfibrils biocontinuous networks 
and 100 nm microballoons with porous shells. 
To date, it has not been possible to make Submicron 
particles by the compressed fluid antisolvent proceSS without 
particle aggregation or flocculation. Our objective is to 
overcome this limitation with the use of Surface modifiers, 
also termed Surfactant Stabilizers, Such as phospholipids, 
Salts of cholic and deoxycholic acids, Tweens 
(polyoxyethylene sorbitan esters), Pluronic F-68, Tetronic 
908, hydroxypropylmethyl cellulose (HPMC), Triton 
X-100, cetyltrimethylammonium bromide, PEG-400 or 












Considerable variations as to the identities and types of 
phospholipid and especially the Surface active agent or 
agents should be expected depending upon the water 
insoluble or poorly water-soluble biologically active sub 
stance Selected as the Surface properties of these Small 
particles are different. The most advantageous Surface active 
agent for the insoluble compound will be apparent following 
empirical tests to identify the Surfactant or Surfactant 
System/combination resulting in the requisite particle size 
and particle size Stability on Storage over time. 
Appropriate choice of Stabilizers will prevent flocculation 
in the aqueous phase. The Surfactant is chosen to be active 
at the compound water interface, but it is not chosen to be 
active at the carbon dioxide-organic Solvent or carbon 
dioxide-drug interface. It is not necessary for the Stabilizer 
to be soluble in CO; it can be soluble in the liquid to be 
sprayed, as it only needs to be active at the CO/Solute 
interface. 
This invention provides a Supercritical fluid/compressed 
fluid based process to produce Suspensions of water 
insoluble drugs with an average particle Size of less than 100 
nm and a narrow Size distribution. An essential element is 
the use of phospholipids and other Surfactants to modify the 
Surface of the drug particles to prevent particle aggregation 
and thereby improve both their Storage Stability and phar 
macokinetic properties. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Materials and methods: Particle sizing was based on the 
principle of photon correlation spectroscopy using Submi 
cron Particle Sizer-Autodilute Model 370 (NICOMP Par 
ticle Sizing Systems, Santa Barbara, Calif.). This instrument 
provides number weighted, intensity weighted, and Volume 
weighted particle size distributions as well as multimodality 
of the particle size distribution, if present. 
Separation and quantitation of cycloSporine was carried 
out with a Waters HPLC system utilizing reverse phase 
chromatography. The drug was extracted from the Sample 
with methanol and injected for analysis on a C-18 analytical 
column at 60-80 C. with a mobile phase consisting of 
acetonitrile, methanol, and water. Anylate was detected 
though its absorbance at 214 nm. Operation of the chroma 
tography System and data processing was conducted by 
Waters Millennium v2.1 Software. 
Carbon dioxide was used to prepare rapid expansion 
Supercritical Solutions since there is no literature reference to 
any chemical interaction with cycloSporine. Carbon dioxide 
has been used as a Solvent for cycloSporine in fermentation 
recovery and in HPLC. The relative solubilities of cyl 
closporine dissolved in a Solvent that is expanded with 
compressed carbon dioxide will be established. 
A gas will approach Sonic terminal Velocity when 
expanded in a nozzle. Therefore it is important to determine 
the maximum nozzle diameter and aspect ratio (L/D) that 
will maintain these conditions in Scaleup. Nozzle diameters 
of 10–50 microns are reported to be used in conjunction with 
aspect ratioS ranging from 5 to 200. 
The apparatus for rapid expansion from Supercritical 
solution shown in FIG. 1 included a high pressure vessel 1 
for formulating the drug/CO Solution. Because the drug 
Solution was isolated from the pressurizing fluid by the 
piston 2 and the valve 2a, the concentration of the drug was 
constant during the Spray. The Solution was mixed with a stir 
bar 14a and a magnetic Stirrer 14. The temperature was 
controlled with heating tape 4. The pressure on the piston 
US 6,974,593 B2 
7 
and hence the drug Solution was controlled via line 3 by an 
automated syringe pump 5 (ISCO model 100DX) containing 
pure carbon dioxide. 
The preheater as shown in FIG. 2A consisted of a hole 
(0.030" i.d. and 4" long) 8a bored axially along the center of 
a 2" o.d.x0.030" i.d.x4" long copper rod to preheat the 
Solution to a desired temperature before expansion. The 
preheater assembly 8 and the expansion valve 7 are con 
nected to the high pressure vessel 1 via outlet tube 6. The 
assembly 8 and the expansion valve 7 were heated with high 
temperature heating tape 12 and were highly insulated. To 
monitor the temperature, a thermocouple 13 was placed 
directly into the preheater assembly close to the orifice. 
The expansion nozzle as shown in more detail in FIG. 2B 
included a 0.254 mm thick, 30 micron diameter laser-drilled 
orifice 11 (length to diameter ratio -8.5), which was placed 
between two copper gaskets 15 (10 mm O.d., 6 mm i.d. and 
1 mm thick) and sealed in a 4" tubing assembly. The 
downstream end of the orifice was counterbored into a 
V-shape as shown in FIG. 2B to prevent the expanding jet 
from hitting the walls and distorting the morphology of the 
precipitating Solute. To prevent plugging of the orifice, a /4" 
inch diameter, 0.5 micron metal filter 9 was inserted 
upstream of the nozzle preheater assembly (FIG. 1). In 
addition, a bypass line 10 was used to pre-pressurize the 
preheater assembly with pure solvent (CO) before each 
Spray, otherwise the initial pressure drop acroSS the filter 
would precipitate the drug and plug the orifice 11. After 
displacing pure Solvent from the preheater, the orifice was 
Submerged into 25 mL acqueous Solution in order to trap and 
Stabilize the precipitating drug microparticles. The high 
kinetic energy of the jet forced the spray 2 cm below the 
Surface of the aqueous phase. 
The apparatus used to carry out the Compressed fluid 
antisolvent sprays is shown in FIG. 3. A 300 mL high 
preSSure vessel 16 equipped with a magnetically coupled 
agitator (Parr) depicted in outline above vessel 16 was used 
to precipitate the drug. Prior to Spraying the drug Solution, 
50 mL of aqueous Solution was added to this precipitator. 
The aqueous solutions were either pure water, 1.0 wt % 
Tween 80 in water 10 wt % phospholipid dispersion in water 
or 10 wt % phospholipid dispersion with 2.0 wt % Tween 80 
in water. Phospholipid and phospholipid plus Tween-80 
dispersions were made by high shear homogenization of 
their aqueous Suspension by passing through a microfluid 
izer (model M110EH, Microfluidics). Tween-80 was pur 
chased from ICI and egg phospholipid was from Pfansthiel. 
Aqueous Sodium hydroxide Solution (1N) was used to adjust 
the pH of these dispersions to 7.5. Carbon dioxide was 
compressed with a Haskel air driven gas booster 17 (model 
AC-152), regulated with a Tescom pressure regulator (model 
26-1021) 18 and monitored by pressure gauge 19. The CO 
pressure was monitored to within +0.2 bar. A water bath with 
a recirculator 30 was used to control the precipitator tem 
perature. The Solution was sprayed through 50 micron i.d. 
fused silica capillary tubing 27 (Polymicro Technology) 
with a length/diameter ratio of 2800. To maintain a constant 
flow rate, the Solution was pumped through the Solution 
Valve 28 to the capillary atomizer using an automated 
syringe pump 20 (ISCO model 100DX). 
A0.5um filter 21 was threaded into the CO effluent line 
22 to prevent loss of the water insoluble compound from the 
precipitation vessel. The filter assembly included an in-line 
sintered filter element (Swagelok “F” series) which was 
welded onto a 4" i.d. NPT fitting. The effluent vent valve 23 
(Whitey, SS-21RS4) connected to rotameter 24 was heated 












CO2 from freezing. During precipitation, a known amount of 
aqueous Solution 25 was agitated using a 45 pitched blade 
impeller 26. After precipitation, agitation was discontinued 
and the vessel was isolated to depressurize for 30–45 min. 
The aqueous Solution was then recovered for particle size 
analysis. 
Unless otherwise Specified, all parts and percentages 
reported herein are weight per unit volume (w/v), in which 
the Volume in the denominator represents the total Volume of 
the System. Diameters of dimensions are given in millime 
ters (mm=10 meters), micrometers (um=10 meters), 
nanometers (nm=10 meters) or Angstrom units (=0.1 nm). 
Volumes are given in liters (L), milliliters (mL=10 L) and 
microliters (uL=10 L). Dilutions are by volume. All tem 
peratures are reported in degrees Celsius. The compositions 
of the invention can comprise, consist essentially of or 
consist of the materials Set forth and the process or method 
can comprise, consist essentially of or consist of the StepS. Set 
forth with Such materials. 
While the invention has been described in connection 
with what is presently considered to be the most practical 
and preferred embodiment, it is to be understood that the 
invention is not to be limited to the disclosed embodiment, 
but on the contrary, is intended to cover various modifica 
tions and equivalent arrangements included within the Spirit 
and Scope of the appended claims. 
The following examples further explain and illustrate the 
invention: 
EXAMPLE 1. 
Cyclosporine Microparticle Formation by the Rapid Expan 
sion from Supercritical Solution Process 
A homogeneous Solution of cycloSporine in Supercritical 
CO was expanded by rapid expansion from Supercritical 
Solution into various aqueous Solutions to Study micropar 
ticle Stabilization. The aqueous Solutions were pure water 
1.0 wt % Tween 80, phospholipid dispersion or 2.0 wt % 
Tween 80 with phospholipid dispersion. An amount of 
0.0480 g of cyclosporine was charged to a variable volume 
view cell and 20 mL of CO were added to formulate a 0.25 
wt % Solution. After the solution came to thermal equilib 
rium (T=35° C) the cyclosporine/CO Solution at 3000 psia 
was sprayed through a 0.30 um orifice (L/D of 8) into an 
aqueous Solution for 25 Seconds. The pre-expansion tem 
perature was 40 C. The volume weighted particle size of the 
cyclosporine microparticles expanded into pure phospho 
lipid was 153.7 nm (peak 2) as shown in FIG. 4. Most of the 
mass that constitutes the peak 1 of 20-50 nm diameter may 
originate largely from the phospholipid; however, this popu 
lation may also possess Some particles that contain 
cyclosporine. The Volume weighted mean particle size of the 
cyclosporine microparticles expanded into phospholipid dis 
persion with 2.0 wt % Tween 80 was 80.9 nm (peak 2) as 
shown in FIG. 5. In this case again the smaller peak (26.8 
nm) may originate largely from the phospholipid and Tween 
80 dispersion and a Small fraction of cycloSporine contain 
ing particulates. A control experiment was performed in 
which pure carbon dioxide at 3000 psia was sprayed into the 
phospholipid dispersion. The mean diameter of the particu 
lates in the dispersion was 9 nm. Therefore, the particles 
greater than 100 nm in FIGS. 4 and 5 were not originating 
from purely the phospholipids, but were drug microparticles. 
Similarly, for the phospholipid dispersion with 2 wt % 
Tween 80, the mean diameter of the was 28 nm. 
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EXAMPLE 2 
Water Insoluble Compound Phase Behavior in Compressed 
CO. 
In order to assess whether a particular water insoluble 
compound should be processed by rapid expansion from 
Supercritical Solution or compressed fluid antisolvent, the 
Solubility of the candidate drugs in carbon dioxide was 
measured. CycloSporine, nife dipline, piro Xicam, 
carbamazepine, indomethacin and tetracaine HI were stud 
ied. To prepare Solutions with a constant molar composition, 
measured amounts of drug and CO were charged to the 
variable volume view cell from Example 1. To increase the 
Solubility, a coSolvent, i.e., acetone or ethanol, was added to 
the view cell. The temperature and pressure were varied 
from 25–45° C. and 1200 to 4500 psia, respectively. The 
phase behavior was determined Visually by noting when 
phase Separation occurred as the pressure was slowly 
reduced at 1-2 psia/Sec. Table 1 shows a Summary of the 
solubility behavior in CO. Cyclosporine was soluble in 
CO2 up to 0.5 wt %. Solutions containing 0.01 wt % 
carbamazepine, tetracaine HI, nifedipine and piroXicam 
were insoluble in CO. With the addition of 2.40 wt % 
acetone, 0.026 wt % piroxicam was soluble in CO at 25 C. 
for all preSSures down to the vapor pressure of CO2, which 
is 930 psia. A solution containing 0.028 wt % nifedipine and 
2.26 wt % acetone cosolvent was insoluble in CO at 25 C. 
At 45 C., the nifedipine was solvated with no visible phase 
separation down to 2000 psia. 
CONC. TEMP. CLOUD POINT 
SOLUTE (wt %) (C) (psia) 
Cyclosporine O.25 25 soluble down to 
12OO 
Cyclosporine O.25 3O 1850 
Cyclosporine O.25 35 2060 
Piroxicam O.069 25 insoluble up to 
45OO 
Nifedipine O.088 25 insoluble up to 
4OOO 
Nifedipine 0.029 (a) 25 insoluble up to 
35OO 
Carbamazepine 0.0085 25, 40 insoluble up to 
45OO 
Tetracaine HI O.O097 25, 45 insoluble up to 
45OO 
Indomethacin O.OO98 25 insoluble up to 
4OOO 
(a) with 2.0% ethanol as a co-solvent. 
EXAMPLE 3 
Indomethacin Microparticle Formation by the Compressed 
Fluid Antisolvent Process 
A 9.9 wt % Solution of indomethacin in acetone was 
Sprayed into carbon dioxide with the aqueous Solution using 
the Compressed fluid antisolvent process. The duration of 
the spray was 30s at 1 mL/min. The volume weighted mean 
particle size of the phospholipid dispersion was 26 nm (peak 
1) as shown in FIG. 6. A bimodal size distribution was 
observed for the indomethacin particles with mean diam 
eters of 143.0 nm (peak 2) and 1088.9 nm (peak 3), 
respectively. Particles with Such a size difference are easily 
Separated by filtration. For the microparticles precipitated 
into phospholipid dispersion in the presence of 2.0 wt % 
Tween 80, the Volume weighted mean particle diameter was 













Tetracaine HI Microparticle Formation by the Compressed 
Fluid Antisolvent Process 
A 0.97 wt % Solution of Tetracaine HI in acetone was 
Sprayed into the precipitator containing carbon dioxide and 
pure water. The Volume weighted mean particle sizes of the 
Tetracaine HI microparticles were 31.8, 193.4 and 2510.1 
nm, respectively (FIG. 8). This illustrates that the Com 
pressed fluid antisolvent process can produce extremely 
small particles even without surfactant stabilizer. With 1.0 
wt % Tween 80 added to the water, three peaks were 
observed with mean diameters of 9.5 nm, 38.3 nm and 169.1 
nm (FIG. 9). The particle size distribution for 1.0 wt % 
Tetracaine HI stabilized with phospholipid dispersion and 
2.0 wt % Tween 80 is shown in FIG. 10. A monomodal 
distribution is observed between 8-200 nm with a mean 
diameter of 27.3 nm. This peak includes both the surfactant 
aggregates and drug particles. No drug particles above 200 
nm were observed. 
What is claimed is: 
1. A process of preparing microparticles up to 300 nm in 
size of water-insoluble or substantially water-insoluble bio 
logically active compounds comprising the Steps of: 
(1) dissolving a water-insoluble or Substantially water 
insoluble biologically active compound in a Solvent 
therefor to form a Solution; and 
(2) Spraying the Solution prepared in step (1) into a 
compressed gas, liquid or Supercritical fluid in the 
presence of a Surface modifier dispersed or dissolved in 
an aqueous phase. 
2. A process of preparing microparticles up to 300 nm in 
size of a water-insoluble or substantially water-insoluble 
biologically active compound comprising the Steps of: 
(1) dissolving a water-insoluble or Substantially water 
insoluble biologically active compound in a com 
pressed fluid, 
(2) preparing an aqueous phase containing a Surface 
modifier active at the compound-water interface, and 
(3) spraying the compressed fluid of Step (1) into the 
aqueous phase of Step (2) to form microparticles of the 
compound. 
3. The process according to claim 1 or 2, including the 
additional Step of recovering the microparticles So produced. 
4. The process according to claim 1 or 2, wherein the 
Surface modifier is a phospholipid. 
5. The process according to claim 1 or 2, wherein the 
Surface modifier is a Surfactant. 
6. The process according to claim 1 or 2, wherein the 
Surface modifier is a mixture of two or more Surfactants. 
7. The process according to claim 1 or 2, wherein the 
Surface modifier is at least one Surfactant devoid or Substan 
tially completely devoid of phospholipids. 
8. The process of claim 1 or claim 2 wherein the surface 
modifier is a polyoxyethylene Sorbitan fatty acid ester, a 
block copolymer of ethylene oxide and propylene oxide, a 
tetrafunctional block copolymer derived from Sequential 
addition of ethylene oxide and propylene oxide to 
ethylenediamine, an alkyl aryl polyether Sulfonate, polyeth 
ylene glycol, hydroxy propylmethylcellulose, Sodium 
dodecylsulfate, Sodium deoxycholate, cetyltrimethylammo 
nium bromide or combinations thereof. 
9. The process of claim 1 or 2 wherein the surface 
modifier is of egg or plant phospholipid or Semisynthetic or 
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Synthetic in partly or fully hydrogenated or in a desalted or 
Salt phospholipid Such as phosphatidylcholine, phospholi 
pon 90H or dimyristoyl phosphatidylglyerol sodium salt, 
phosphatidylethanolamine, phosphatidylserine, phospha 
tidic acid, lySophospholipids or, combinations thereof. 
10. The process of claim 1 or 2 wherein the compound is 
a cyclosporine, indomethacin, or tetracaine. 
11. The process of claim 1 or 2 wherein the particles are 
less than 100 nm in size. 
12. The process of claim 1 or 2 wherein the particles range 
from 5 up to about 50 nm in size. 
13. The process of claim 1 or 2 wherein 99% of the 
particles produced are below 500 nm. 
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14. The process of claim 1 or 2 wherein 99% of the 
particles produced are below 400 nm with peaks at half 
width at half height at about 200 nm. 
15. The process of claim 14 when the peaks are below 100 
. 
16. The process of claim 1 or 2 wherein the compressed 
gas or fluid is gas, liquid or Supercritical carbon dioxide. 
17. The process according to claim 2, wherein the com 
pressed fluid sprayed in Step (3) is sprayed through a 
capillary orifice. 
